REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
23/03/2026
Voltar para busca
Dado oficial do USPTO
IFOM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
24/03/2026
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
20/09/2018
Data de registro
23/03/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/03/2021
Última transação
24/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
12
Localização do titular
IT
Examinador
EBAUGH, MICHAEL
Unidade examinadora
L80
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "IFOM" in special characters and underlined by a line. Moreover, a stylized representation of a microscope starts from the line and partially overlaps with the letter "O".
Titulares e representantes
Titulares
I. M. (pessoa física)
Representantes
KENNETH F FLOREK FLOREK & ENDRES PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for use in hematology; pharmaceutical preparations for the prevention of disorders of the skeletal system; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the treatment of disorders of the central nervous system related to canceraging and metabolic diseases; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of disorders of the circulatory system related to aging; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of hormonal disorders and diabetes; pharmaceutical cough preparations; preparations for treating colds; pharmaceutical preparations for the treatment of flu and headache; pharmaceutical preparations for the treatment of stomach disorders; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for treating muscular and/or rheumatological diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergies; pharmaceutical agents affecting metabolism; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for use in oncology; diagnostic preparations and reagents for medical use in a clinic or medical laboratory; hormones; dietetic substances adapted for medical usein particularnutritional supplementsvitamin preparationsherbal supplements and preparationsnutritional drink mixes for use as meal replacements for medical usemeal replacement snacks for medical purposes; food and drinks for babiesinfant formula and dietetic products for invalidsin particular food for babiespowdered milk for babiesfoods for enteral feedings and dietetic foods adapted for medical purposes
Classe 42
Scientific and technological servicesscientific researchanalysistestingdiagnosis and screening in the field of oncology and cancer research; research and development in the field of oncologyaging and metabolic diseases; scientific and industrial research and analysis servicesscientific researchanalysistesting in the field of medicine; biological research and analysis; scientificclinical and medical research in the field of radiologychemotherapypharmacotherapycoronary artery bypass surgery; basic and clinical research in the field of geneticsstem cellimmunodeficiency and neurodegenerative diseasesproteomicsbioinformaticsneurobiology and molecular biology and diabetes; scientific research in the field of medicine; consultancy in the field of scientific analysis; none of the foregoing to include educational testing
Classe 44
Medical serviceshealth care services in the field of oncologyaging and metabolic diseasesmedical assistancephysical rehabilitation in the field of oncology; hospital services; consulting services in the field of medical careconsultancy in the field of medical diagnosismedical analysis and RNA or DNA analysis for cancer diagnosis and prognosis; consulting services relating to health care
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/05/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/08/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
01/07/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
01/07/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
23/06/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
23/03/2021
TMBN
TTAB RELEASE CASE TO TRADEMARKS
16/02/2021
OP.T
OPPOSITION TERMINATED NO. 999999
16/02/2021
OP.D
OPPOSITION DISMISSED NO. 999999
16/02/2021
RFNP
REFUSAL PROCESSED BY IB
26/12/2020
OP.I
OPPOSITION INSTITUTED NO. 999999
07/12/2020
OPNS
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
01/12/2020
OPNC
OPPOSITION NOTICE (IB REFUSAL) CREATED
01/12/2020
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/10/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/09/2020
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
23/09/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
30/06/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/06/2020
PUBO
PUBLISHED FOR OPPOSITION
02/06/2020
GPNX
NOTIFICATION PROCESSED BY IB
29/05/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/05/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
13/05/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/05/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/04/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
17/04/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
17/04/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
17/04/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
17/04/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
17/04/2020
PBSR
WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST
18/12/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/12/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
10/12/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/12/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
10/12/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/12/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/11/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/11/2019
ALIE
ASSIGNED TO LIE
18/11/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/11/2019
RFNT
REFUSAL PROCESSED BY IB
22/06/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
31/05/2019
RFRR
REFUSAL PROCESSED BY MPU
31/05/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/05/2019
CNRT
NON-FINAL ACTION WRITTEN
07/05/2019
MAFR
APPLICATION FILING RECEIPT MAILED
04/05/2019
DOCK
ASSIGNED TO EXAMINER
30/04/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/04/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
29/04/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IFOM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.